iCAT for Recurrent/Refractory/HR Solid Tumors

Completed

Conditions studied: Pediatric Solid Tumor, Sarcoma, Neuroblastoma, Wilms Tumor

In brief

In this study tumor will be tested for cancer causing gene alterations such as mutations or copy number alterations. This is called tumor profiling. A panel of experts will review the tumor profiling results and determine whether there is a cancer-causing alteration present in the tumor. If there is, the experts will determine if there is a targeted drug available that could counteract this alteration. If there is an alteration identified and a targeted drug available the panel of experts will make an individualized treatment recommendation. The results of the tumor profiling and the individualized treatment recommendation can be shared with the primary oncologist.

Key facts

Study ID

NCT01853345

Run by

Dana-Farber Cancer Institute

People needed

101

Starts

2012-08-01

Last updated by the study team

2015-02-10

Who can join

Age: any, up to 30. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of recurrent, refractory of high risk pediatric solid tumor (excluding brain tumor)
• Histologic proof of malignancy at the time of diagnosis or recurrence
• Sufficient tumor specimen available for profiling from diagnosis or recurrence, or surgery/biopsy planned for clinical care

You may not qualify if…

• Brain tumors

Where it is running

• University of California, San Francisco — San Francisco, California, United States
• Children's National Medical center — Washington D.C., District of Columbia, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Boston Children's Hospital — Boston, Massachusetts, United States
• Columbia University — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.